BTBD17 Activators
BTBD17 Activators comprise a range of chemical compounds that indirectly facilitate the functional activation of BTBD17 through diverse signaling mechanisms within the cell. Forskolin and IBMX both act to elevate intracellular cAMP levels, with forskolin directly stimulating adenylate cyclase and IBMX inhibiting cAMP degradation by phosphodiesterases. The resulting increase in cAMP activates PKA, which may phosphorylate proteins involved in the regulation of BTBD17, leading to its enhanced activity. Okadaic Acid, Calyculin A, and Anisomycin alter the phosphorylation landscape of the cell; Okadaic Acid and Calyculin A inhibit protein phosphatases, preserving the phosphorylated state of proteins, while Anisomycin activates stress-activated protein kinases, possibly facilitating BTBD17 activation through stress response pathways. Epigallocatechin Gallate and Staurosporine may shift kinase activity equilibria, potentially favoring BTBD17 activation by modulating the activities of kinases that regulate its signaling pathways.
The activity of BTBD17 is further influenced by compounds that impact central cellular signaling pathways. PMA, as a PKC activator, and the PI3K inhibitor LY294002, modBTBD17 Activators comprise a range of chemical compounds that indirectly facilitate the functional activation of BTBD17 through diverse signaling mechanisms within the cell. Forskolin and IBMX both act to elevate intracellular cAMP levels, with forskolin directly stimulating adenylate cyclase and IBMX inhibiting cAMP degradation by phosphodiesterases. The resulting increase in cAMP activates PKA, which may phosphorylate proteins involved in the regulation of BTBD17, leading to its enhanced activity. Okadaic Acid, Calyculin A, and Anisomycin alter the phosphorylation landscape of the cell; Okadaic Acid and Calyculin A inhibit protein phosphatases, preserving the phosphorylated state of proteins, while Anisomycin activates stress-activated protein kinases, possibly facilitating BTBD17 activation through stress response pathways. Epigallocatechin Gallate and Staurosporine may shift kinase activity equilibria, potentially favoring BTBD17 activation by modulating the activities of kinases that regulate its signaling pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin directly stimulates adenylate cyclase, increasing cAMP levels. Elevated cAMP activates protein kinase A (PKA), which can phosphorylate downstream targets that may include regulators of BTBD17, leading to its functional activation. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a non-selective inhibitor of phosphodiesterases (PDEs). By preventing cAMP degradation, IBMX maintains elevated levels of cAMP, which enhances PKA activity, potentially enhancing BTBD17 activity indirectly. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $285.00 $520.00 $1300.00 | 78 | |
Okadaic Acid is a potent inhibitor of protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This compound could indirectly increase the phosphorylation state of BTBD17 or its regulators, leading to enhanced activity. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin gallate (EGCG) is known to inhibit several protein kinases. By modulating specific kinase activities, EGCG may shift the equilibrium in signaling pathways to favor the activation of BTBD17. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $97.00 $254.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that also activates stress-activated protein kinases (SAPKs). The activation of these kinases could lead to the indirect activation of BTBD17 through stress response pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor, which could lead to selective activation of BTBD17-related pathways by altering the balance of kinase activities within the cell. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is a diacylglycerol (DAG) analog and a potent activator of protein kinase C (PKC). PKC activation could lead to downstream effects that enhance the activity of BTBD17. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is an inhibitor of phosphatidylinositol 3-kinase (PI3K). Inhibition of PI3K can modulate various signaling pathways and might indirectly enhance BTBD17 activity by reducing competitive signaling pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, which prevents the activation of the MAPK/ERK pathway. This could lead to the reallocation of cellular resources to pathways that upregulate BTBD17 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mTOR pathway, which might allow for the indirect activation of BTBD17 by reducing negative feedback loops that inhibit pathways involved in BTBD17 activation. | ||||||